Pionyr Immunotherapeutics Inc.   Report issue

For profit Phase 1
Founded: San Francisco CA United States (2015)
Status: Acquired by Ikena Oncology (2023)

Organization Overview

First Clinical Trial
2020
NCT04691375
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Pionyr Immunotherapeutics Inc. | Pionyr Immunotherapuetics, Inc.

Active Ingredients

Drugs in Phase 1 Trials (3)

pembrolizumab (keytruda) (1 trial)

py159 (1 trial)

py314 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 3